Status unknownNCT01679847Updated Sep 10, 2012

Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

An observational study in Cancer, sponsored by Dalian Holley Kingkong Pharmaceutical Co., Ltd. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2012-09-10.

Sponsored by Dalian Holley Kingkong Pharmaceutical Co., Ltd · Observational

The sponsor has not verified this record recently (last verified Sep 2012), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Case-only
Enrollment: 8
Sex: All

Study summary

The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.

Conditions studied

Cancer

Keywords

Elemene
pharmacokinetics
Blood-brain barrier

In context

Lead sponsor

This is the only study on the registry with Dalian Holley Kingkong Pharmaceutical Co., Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

malignant patients

Inclusion criteria

histopathological or cytopathology diagnosis of malignancy
heart, liver and renal function is normal
Expected survival time is more than 3 months
Signed informed consent

Exclusion criteria

exclusion Criteria:

non cancer patient
accepted elemene administration in 1 month
Expected survival time is less than 3 months
no Signed informed consent
heart, liver and renal function is abnormal

Study design

Observational model: Case-only
Enrollment: 8 participants (estimated)
Biospecimen retention: Samples without dna

What researchers measure

Primary outcomes

blood and cerebrospinal fluid concentration
Time frame: 0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose

Study locations

1 site

Huashan Hospital of Fudan University
Shanghai, Shanghai 200040, China

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Sep 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01679847
Lead sponsor: Dalian Holley Kingkong Pharmaceutical Co., Ltd
Responsible party: Sponsor
First posted: Sep 6, 2012
Start date: Sep 2012
Primary completion: Apr 2013 (estimated)
Completion: Jun 2013 (estimated)
Last update: Sep 10, 2012

Study contacts

ZHAN QIONG, MD

Contact

zjoan2121@gmail.com

8621-52887162

liang xiaohua, phD

principal investigator · Huashan Hospital

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion